| Symbol |
CTSD |
| Full Name |
Cathepsin D |
| Aliases |
CPSD, CLN10 |
| Chromosome |
11p15.5 |
| NCBI Gene |
1509 |
| Ensembl |
ENSG00000103811 |
| UniProt |
P07339 |
| Diseases |
[Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers-disease) |
| Expression |
Brain, liver, macrophages, neurons, microglia |
Cathepsin D is a lysosomal aspartic protease encoded by the CTSD gene. It is one of the major lysosomal proteases responsible for protein degradation, cellular turnover, and autophagy. CTSD plays a dual role in neurodegeneration — it can promote cell death through apoptotic mechanisms, but also serves as a critical component of the autophagy-lysosome pathway that clears alpha-synuclein and amyloid-beta. CTSD dysfunction has been implicated in both Alzheimer's disease and Parkinson's disease.
¶ Gene and Protein Structure
CTSD is located on chromosome 11p15.5 and encodes a 412-amino acid protein. The mature enzyme is generated through a multi-step process:
- Pre-proenzyme: Signal peptide + prosegment + mature enzyme
- Procathepsin D (48 kDa): Secreted/lysosomal form with prosegment
- Mature cathepsin D (34 kDa): Activated protease consisting of light and heavy chains
The active site contains two aspartic acid residues that coordinate a water molecule for peptide bond hydrolysis.
Cathepsin D is essential for lysosomal proteolysis:
- Bulk protein turnover: Degrades long-lived proteins in lysosomes
- Autophagy substrate clearance: Processes material delivered via autophagosomes
- Precursor processing: Activates other enzymes and processes hormones and growth factors
CTSD functions as a key executioner in the autophagy pathway:
- Autophagosome-lysosome fusion: CTSD activity required for this step
- Aggregate clearance: Degrades protein aggregates including alpha-synuclein
- Organelle turnover: Breaks down mitochondria (mitophagy) and other organelles
- Cell survival regulation: Modulates apoptosis through Bcl-2 family interactions
- Growth factor processing: Generates bioactive peptides from precursors
- Immune function: Processes antigens for MHC presentation
In Alzheimer's disease, CTSD has complex and potentially dual roles:
Amyloid-beta metabolism: CTSD can both generate and degrade amyloid-beta:
- Cleaves APP to produce amyloid-beta fragments
- Degrades extracellular amyloid-beta plaques
- Dysregulation contributes to amyloid accumulation
Neuronal vulnerability: CTSD deficiency leads to:
- Lysosomal storage abnormalities
- Accumulation of lipofuscin (age pigment)
- Impaired neuronal survival
CTSD deficiency causes lysosomal dysfunction that drives alpha-synuclein aggregation:
- Loss of CTSD impairs autophagosome-lysosome fusion
- Alpha-synuclein accumulates in toxic oligomeric forms
- Dopaminergic neurons are particularly vulnerable
- Mouse models show PD-like motor phenotypes
CTSD dysregulation contributes to multiple system atrophy pathology:
- Glial cytoplasmic inclusions contain alpha-synuclein
- CTSD activity is altered in affected brain regions
- Neuroinflammation is modulated by CTSD status
flowchart TD
subgraph Normal_Function
A["CTSD Gene<br/>(11p15.5)"] --> B["Procathepsin D<br/>(48 kDa)"]
B --> C["Mature Cathepsin D<br/>(34 kDa)"]
C --> D["Protein<br/>Degradation"]
C --> E["Autophagy<br/>Substrate Clearance"]
C --> F["Aggregate<br/>Removal"]
end
subgraph Neurodegeneration
G["CTSD Deficiency<br/>or Dysfunction"] --> H["Impaired<br/>Lysosomal Fusion"]
H --> I["Autophagosome<br/>Accumulation"]
I --> J["Alpha-Synuclein<br/>Aggregation"]
I --> K["Amyloid-Beta<br/>Accumulation"]
J --> L["Neuronal<br/>Death"]
K --> L
G --> M["Apoptotic<br/>Signaling"]
M --> L
end
subgraph Therapeutic_Target
N["CTSD<br/>Activation"] --> O["Enhanced<br/>Lysosomal Activity"]
O --> P["Improved<br/>Aggregate Clearance"]
P --> Q["Neuroprotection"]
N --> R["Reduced<br/>Apoptosis"]
R --> Q
end
classDef blue fill:#e1f5fe,stroke:#333
classDef green fill:#c8e6c9,stroke:#333
classDef red fill:#ffcdd2,stroke:#333
classDef purple fill:#f3e5f5,stroke:#333
click A "/genes/ctsd" "CTSD Gene"
click C "/mechanisms/autophagy-pathway" "Autophagy Pathway"
click D "/mechanisms/lysosome-dysfunction" "Lysosome Dysfunction"
click J "/mechanisms/synucleinopathy" "Synucleinopathy"
click K "/diseases/alzheimers-disease" "Alzheimer's Disease"
click L "/diseases/parkinsons-disease" "Parkinson's Disease"
Increasing CTSD activity represents a therapeutic approach for neurodegenerative disease:
- Small molecule activators: Enhance CTSD maturation and activity
- Gene therapy: AAV-mediated CTSD expression
- Protein replacement: Exogenous CTSD delivery
Since CTSD is central to autophagy-lysosome function:
- mTOR inhibitors (rapamycin, everolimus) induce autophagy upstream
- Combined approach: increase flux (upstream) plus enhance clearance (CTSD)
CTSD and GBA1 converge on the lysosomal pathway:
- GBA1 deficiency impairs glycolipid degradation and affects CTSD maturation
- Both deficiencies lead to alpha-synuclein accumulation
- Combined targeting may be more effective than single approach
Key questions in CTSD biology and therapy:
- How does CTSD deficiency specifically affect dopaminergic neurons?
- Can pharmacological CTSD activation provide neuroprotection in vivo?
- What is the relationship between CTSD and other lysosomal genes (GBA1, LRRK2)?
- Are CTSD promoter variants associated with disease progression?